Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CBLB | Q13191 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773863 | 1.00 | PLA2G2A (0.36) | PLA2G2AADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL1401053 | 0.92 | PLA2G2A (0.36) | PLA2G2AALDH1A1LMNACBLB | |
| SCHEMBL3780082 | 0.91 | ABCG2 (0.36) | PLA2G2AALDH1A1LMNACBLB | |
| SCHEMBL3779589 | 0.91 | PLA2G2A (0.36) | PLA2G2A | |
| SCHEMBL5493627 | 0.90 | POLB (0.38) | — | |
| SCHEMBL3809767 | 0.82 | CYSLTR1 (0.41) | PLA2G2AALDH1A1LMNA | |
| SCHEMBL3773865 | 0.81 | PLA2G2A (0.41) | PLA2G2AALDH1A1LMNA | |
| SCHEMBL1401054 | 0.81 | PLA2G2A (0.38) | PLA2G2AALDH1A1LMNACBLB | |
| SCHEMBL1401180 | 0.81 | PLA2G2A (0.38) | PLA2G2AALDH1A1CBLB | |
| SCHEMBL12927207 | 0.81 | PLA2G2A (0.50) | PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110137039-A1 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS | MYLAN LABORATORIES LIMITED (IN) | 2011-06-09 | — | — | US | disclosed |
| US-20110092708-A1 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS THEREOF | MYLAN LABORATORIES LIMITED (IN) | 2011-04-21 | — | — | US | disclosed |
| EP-1812394-B1 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS | MATRIX LAB LTD (IN) | 2011-03-02 | — | — | EP | disclosed |
| US-7858793-B2 | Methyl 2-[(3S)-[3-[2E)-(7-chloro quinolin-2-yl) ethenyl] phenyl]-3-halopropyl] benzoates | SATYANARAYANA CHAVA | 2010-12-28 | — | — | US | disclosed |
| US-7858793-B2 | Methyl 2-[(3S)-[3-[2E)-(7-chloro quinolin-2-yl) ethenyl] phenyl]-3-halopropyl] benzoates | SATYANARAYANA CHAVA | 2010-12-28 | — | — | US | disclosed |
| EP-2069307-A2 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS THEREOF | Matrix Laboratories Ltd (IN) | 2009-06-17 | — | — | EP | disclosed |
| US-20090143590-A1 | Process for the Preparation of Montelukast and its Salts | MATRIX LABORATORIES LTD. (IN) | 2009-06-04 | — | — | US | disclosed |
| US-20080275243-A1 | Process for the Preparation of Polymorphs, Solvates of Aripiprazole Using Aripiprazole Acid Salts | SATYANARAYANA CHAVA | 2008-11-06 | — | — | US | disclosed |
| US-20080275243-A1 | Process for the Preparation of Polymorphs, Solvates of Aripiprazole Using Aripiprazole Acid Salts | SATYANARAYANA CHAVA | 2008-11-06 | — | — | US | disclosed |
| US-20080146809-A1 | Process for the Preparation of Novel Amorphous Montelukast Sodium | MATRIX LABORATORIES LTD (IN) | 2008-06-19 | — | — | US | disclosed |
| WO-2008015703-A2 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS THEREOF | MATRIX LABORATORIES LTD (IN) | 2008-02-07 | — | — | WO | disclosed |
| EP-1831171-A1 | PROCESS FOR THE PREPARATION OF NOVEL AMORPHOUS MONTELUKAST SODIUM | Matrix Laboratories Ltd (IN) | 2007-09-12 | — | — | EP | disclosed |
| EP-1812393-A2 | \"METHYL 2-[(3S)-[3-[(2E)-(7-CHLORO QUINOLIN-2-YL) ETHENYL] PHENYL]-3-HALOPROPYL] BENZOATES” | Matrix Laboratories Ltd (IN) | 2007-08-01 | — | — | EP | disclosed |
| EP-1812394-A2 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS | Matrix Laboratories Ltd (IN) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006008750-A3 | METHYL 2-[(3S)-[3-[(2E)-(7-CHLORO QUINOLIN-2-YL) ETHENYL] PHENYL]-3-HALOPROPYL] BENZOATES | MATRIX LAB LTD (IN) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006054317-A1 | PROCESS FOR THE PREPARATION OF NOVEL AMORPHOUS MONTELUKAST SODIUM | MATRIX LABORATORIES LTD (IN) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006008750-A2 | METHYL 2-[(3S)-[3-[(2E)-(7-CHLORO QUINOLIN-2-YL) ETHENYL] PHENYL]-3-HALOPROPYL] BENZOATES | MATRIX LABORATORIES LTD (IN) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006008751-A2 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS | MATRIX LABORATORIES LTD (IN) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143590-A1 | Process for the Preparation of Montelukast and its Salts | CMA1, CYSLTR1, CYSLTR2 | PLA2G2A 3342/4885ADRB2 100/4885ADRB1 47/4885 |
| US-20110092708-A1 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS THEREOF | CMA1, LTC4S, LTA4H | PLA2G2A 2394/4885ADRB2 200/4885ADRB1 71/4885 |
| US-20080275243-A1 | Process for the Preparation of Polymorphs, Solvates of Aripiprazole Using Aripiprazole Acid Salts | HTR3C, HTR3B, TPMT | PLA2G2A 3773/4885ADRB2 452/4885ADRB1 668/4885 |
| US-20110137039-A1 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS | MPST, CMA1, LTC4S | PLA2G2A 3274/4885ADRB2 182/4885ADRB1 106/4885 |
| US-20080146809-A1 | Process for the Preparation of Novel Amorphous Montelukast Sodium | CMA1, MAST1, MAST3 | PLA2G2A 3289/4885ADRB2 1385/4885ADRB1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.